In the article by Panzer-Grümayer et al entitled “Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia,” which appeared in the February 1, 2000, issue of Blood (Volume 95: 790–794), a correction should be noted regarding the treatment protocol: All children stratified into SRG and MRG received induction treatment (protocol 1), consolidation treatment (protocol M), and reinduction treatment (protocol 2), followed by maintenance treatment. Protocol 2 was omitted in the original article. It consisted of phase 1 with daily dexamethasone for 3 weeks, weekly vincristine and doxorubicin ×4 starting at week 2, and 1-asparaginase ×4 during weeks 2 and 3, followed by phase 2 with cyclophosphamide on day 36, ARA-C 4×/wk plus intrathecal methotrexate on days 38 and 45.
Skip Nav Destination
ERRATUM|
May 15, 2000
Erratum in Panzer-Grümayer et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.
Blood (2000) 95 (10): 3010.
Connected Content
Citation
Erratum in Panzer-Grümayer et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.. Blood 2000; 95 (10): 3010. doi: https://doi.org/10.1182/blood.V95.10.3010
Download citation file:
May 15 2000
Advertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal